South Korean Exchange Cancels SCM Life Science Management Project Designation... Investor Confusion Rises↑

The Korean exchange reversed its decision to delist SCM Life Sciences within a day, causing sharp stock price fluctuations. This incident has confused investors, and the exchange has begun developing measures to prevent similar events from happening again.

On the 16th of this month, the Korea Exchange’s KOSDAQ Market Headquarters lifted the delisting order for SCM Life Sciences, citing improvements in its operational indicators. However, they soon discovered an error and restored the original status the following afternoon. The exchange stated that they misjudged the company’s submitted audit report, specifically the deduction of corporate income tax expenses before continuing operations, believing it met the delisting criteria, and thus announced the removal.

Lifting the delisting usually indicates an improvement in the company’s operational condition. As a result, SCM Life Sciences’ stock price hit the daily limit early in the trading session, soaring 28.05%. However, after the delisting was reinstated, the stock price reversed course and fell, closing down 5.73%. This volatility caused unnecessary confusion and financial losses for investors.

The Korea Exchange announced that an internal investigation into the incident is underway. They are also working on introducing AI technology to improve disclosure systems and are considering holding relevant personnel accountable if necessary. At the same time, they emphasized their commitment to ensuring market stability.

Going forward, to prevent such incidents from recurring, it is essential to strengthen the credibility of the exchange and the accuracy of disclosures. Experts believe that addressing these technical issues will play a key role in maintaining investor trust.